The average time to when patients require a wheelchair could be extended from 12 years to 16.3 years.
News
BMS’ Opdivo shows long-term survival benefit
Opdivo-treated patients continued to experience long-term overall survival benefits compared to docetaxel.
Scotland and Vertex strike CF drug deal
Back in August, the SMC rejected Orkambi and Symkevi following consideration through PACE.
MSEA 2018 winner shares how the finals day has helped to enhance his area of expertise
The 2018 winner of the New Medical Science Liaison of the Year shares his experience with the competition and how it has helped to sharpen his skills.
Parsortix test could avoid unnecessary prostate biopsies
Currently, investigation of symptoms for prostate cancer is typically made via an invasive blood test.
Merck initiates late-stage MS study
The previous Phase II trial met its primary endpoint.
Gilead, Elton John AIDS Foundation launch HIV initiative
The pharma giant announced the “ground-breaking” RADIAN initiative at the Fast-Track Cities 2019 conference in London.
Government injects £130m into cancer & debilitating illnesses
Thousands of NHS patients could receive faster diagnosis and better treatment for life-changing diseases like cancer, dementia and Parkinson’s.
Kymriah leads latest round of SMC decisions
MSD’s Keytruda, Pfizer’s Visimpro, AstraZeneca’s Forxiga and Shionogi’s Senshio were also accepted.
Final chance to enter into the 2019 Sales Awards!
The 2019 PharmaTimes Sales Awards will be closing for entry midnight on Friday – this is the last chance for sales professionals to enter.
Cassava’s lead Alzheimer’s candidate hits endpoints
The new treatment could be an “important part of the research dialogue in Alzheimer’s disease.”
Bayer’s two-year data confirms Eylea effectiveness
Wet AMD is a serious and debilitating sight-threatening condition that requires ongoing treatment to prevent worsening.
Spravato reduces depressive symptoms in 24 hours
Both studies showed clinically meaningful and statistically significant superiority of the drug.
PRAC to review Picato skin cancer data
The committee will now carry out a thorough review of all available data, including from ongoing studies.
NHS to review making statins available for pharmacists
If only 45% of people with a high risk of cardiovascular disease were identified and treated, 6,000 strokes and heart attacks could be avoided over the next ten years.
